Jodella Locklear
Family · Pembroke, NCNPI 1578565164
Payments from drug & device makers
Across 81 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$222
- Novo Nordisk$188
- AstraZeneca$138
- Lilly USA, LLC$124
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$107
- Sanofi-aventis U.S. LLC$81
- plus $399 from 13 others
What the payments were for
- Food & beverage$1,260100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $222 |
| Novo Nordisk | 11 | $188 |
| AstraZeneca | 8 | $138 |
| Lilly USA, LLC | 8 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Boehringer Ingelheim | 4 | $65 |
| Pfizer | 3 | $65 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Abbott | 1 | $24 |
| Merck | 2 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| GSK | 1 | $14 |
| Nevro Corp. | 1 | $13 |
How this compares
$1,260 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $85,004 |
| LinzessLinaclotide | 57 | $67,188 |
| TrulicityDulaglutide | 38 | $64,989 |
| JanuviaSitagliptin Phosphate | 32 | $49,536 |
| MounjaroTirzepatide | 29 | $42,615 |
| JardianceEmpagliflozin | 34 | $42,421 |
| EliquisApixaban | 27 | $32,483 |
| TradjentaLinagliptin | 26 | $28,039 |
| FarxigaDapagliflozin Propanediol | 23 | $26,862 |
| XareltoRivaroxaban | 29 | $22,354 |
| Repatha SureclickEvolocumab | 11 | $6,186 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $6,023 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 139 | $5,479 |
| Gabapentin | 395 | $5,137 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $4,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $124 | $107,60467 claims |
| Novo NordiskOzempic | $188 | $85,00464 claims |
| Boehringer IngelheimJardiance, Tradjenta | $65 | $70,46060 claims |
| AbbVieLinzess | $222 | $67,18857 claims |
| MerckJanuvia | $23 | $49,53632 claims |
| PfizerEliquis | $65 | $32,48327 claims |
| AstraZenecaFarxiga | $138 | $26,86223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.
Other family in Pembroke
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.